News
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
1d
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
1d
HealthDay on MSNModerna’s New Flu Shot Shows Strong Results in Older AdultsAn mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...
Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...
Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...
Two young elephants at the Cincinnati Zoo, Sanjay and Kabir, overcame a deadly virus thanks to a new vaccine introduced to ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results